Kore Private Wealth’s BioMarin Pharmaceuticals BMRN Stock Holding History

Kore Private Wealth’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-60	Closed	-$7K	–	371
2020 Q2	$7K	Buy	60 +46	+329%	+$4.57K	﹤0.01%	849
2020 Q1	$1K	Hold	14	–	–	﹤0.01%	965
2019 Q4	$1K	Buy	+14	New	+$1.06K	﹤0.01%	969
2019 Q2	–	Sell	-27	Closed	-$2K	–	298
2019 Q1	$2K	Sell	27 -20	-43%	-$1.85K	﹤0.01%	843
2018 Q4	$4K	Buy	+47	New	+$4.47K	﹤0.01%	711

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Kore Private Wealth's BMRN Position: Q3 2020 in Review

Kore Private Wealth sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2020, closing a stake of 60 shares — an estimated $7K sold.

Kore Private Wealth first reported a position in BMRN in Q4 2018 and held it in 5 quarters. The position peaked at $7K in Q2 2020. 496 funds tracked by Wall St. Rank hold BMRN as of Q3 2020.

Kore Private Wealth reported no remaining BioMarin Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Kore Private Wealth sold 60 BioMarin Pharmaceuticals shares in Q3 2020, an estimated $7K.
Kore Private Wealth first reported a position in BioMarin Pharmaceuticals in Q4 2018 and held it in 5 quarters.
Kore Private Wealth's BioMarin Pharmaceuticals position peaked at $7K in Q2 2020.
496 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2020.

Based on Kore Private Wealth's 13F filing for Q3 2020, filed 13 Nov 2020.